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public sectors primarily in the following areas: regulation and competition, innovation, 
regional economy and indUnited Statestrial politics and health economics.   
Research results are disseminated through publications, conferences and colloquia. 
These activities are aimed to foster cooperation between the private sector and public 
administrations, as well as the exchange of ideas and initiatives.  
The sponsors of the SP-SP Center are the following:  
•  Accenture 
•  Ajuntament de Barcelona 
•  Caixa Manresa 
•  Cambra Oficial de Comerç, Indústria i Navegació de Barcelona 
•  Consell de l’Audiovisual de Catalunya 
•  Departamento de Economía y Finanzas de la Generalitat de Catalunya 
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Biotechnology is considered one of the key engines to achieving long-term sustainable growth. 
Catalonia is the main player in the Spanish biotechnology market, boasting 35 percent of the 
Spanish biotech R&D and 24 percent of its firms. In this report, we analyze the state of the 
Catalan biotechnology sector, focusing on its competitive advantages and disadvantages relative 
to other European biotech clusters. Our findings indicate that, in Catalonia, the biotechnology 
sector has the potential to affect sectors that represent 10 percent of the Catalan GDP and that 
employ 9.3 percent of the Catalan workforce. However, Catalan biotech is still quite small in 
relation to the top European bioclusters and it is only slowly catching up in some of its strategic 
components. The main advantages of the Catalan biotechnology sector are, first, its research 
effort, which has been improving steadily and that, especially in industrial biotechnology, has 
allowed Catalonia to start closing the gap with Europe. Second, the attractiveness of Barcelona to 
draw key staff. The main challenge it faces is access to funding and the fact that the size of 
related industries in the area is smaller than their size in the top European biotech regions. 
Finally, 65 percent of the Catalan biotechnology firms are devoted to the health sector, while the 
performance of biotech research in the industrial sector has been particularly competitive. 
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BIOTECHNOLOGY IN CATALONIA. 
INDUSTRY ANALYSIS 
 
“We used to think our future was in the stars. Now we know it is in our genes.” 
James Watson 
 
Even though the exact link between research, innovation and economic growth is still not fully 
understood, the evidence of the importance of technology for economic growth in the economic 
literature is overwhelming. The recognition that the future of many businesses relies on the 
development of sound technologies is gaining adepts. In this context, it is not surprising that 
the development of science related to the biotechnology sector is rapidly gaining priority in 
many political and industrial agendas as more and more countries are considering it a key 
engine to achieving long-term sustainable economic and job growth. In fact, it is already 
specifically mentioned as one of the key strategic areas of the Spanish Plan Nacional de I+D+I 
2008-1011; the Lisbon Agenda
1 and the EU Sustainable Development Strategy.
2 
Catalonia is one of the key biotechnology regions in Spain. It counts for 35 percent of the 
Spanish R&D expenditure in biotechnology and it is home to 24 percent of the Spanish biotech 
firms.
3 However, the number of studies analyzing the relevance of Catalan biotechnology is 
very scarce, due, in part, to the lack of data on the Catalan biotech sector – for instance, 
biotech firms are not separately classified as such in the Idescat Database. Against this 
background, the aim of this report is to analyze the state of biotechnology in Catalonia and to 
present it in the worldwide context in order to understand the potential sources of competitive 
advantage/disadvantage of the region. Understanding the competitive position of Catalan 
biotech and its potential future prospects is particularly relevant because biotechnology is 
considered as a strategic sector by the government. 
                                              
NOTE: With the collaboration of Javier Botella.  
 
1 EU (2000), "Presidency Conclusions: Lisbon European Council 23 and 24 March," DOC/00/8. European Commission, 
Brussels. 
2 European Commission COM (2001) 264 final: Communication from the Commission – a sustainable Europe for a 
better world: a European Union strategy for Sustainable Development (Commission’s proposal to the Gothenburg 
European Council). 
3 Asebio, 2007.  
 
2 -  IESE Business School-University of Navarra 
1. What is Biotechnology? 
The OECD defines biotechnology as «the application of science and technology to living 
organisms, as well as parts, products and models thereof, to alter living or non-living materials 
for the production of knowledge, goods and services». Hence, as its name indicates, 
biotechnology is not a sector but a technology and as such it can have potential applications to 
a wide variety of industries. A color code is often used to facilitate the identification of those 
fields of application. Depending on the industries in which it is applied, biotechnology can be 
classified in four groups. The healthcare sector (red biotech) makes the greatest use of 
biotechnology. Here its science is employed in treating, diagnosing and preventing disease. In 
addition, biotechnology is widely used in agriculture (green biotech) and in the production of 
agro-food in general. Biotechnology is also applied in industry (white biotech), in the 
production of biochemicals, biomaterials and biofuels. Finally, blue biotechnology is a term 
that has been used to describe the marine and aquatic applications of biotechnology, but its use 
is, so far, relatively rare.  
Biotechnology is, first and foremost, a science-based business where the quality of science is a 
key determinant for the economic value of the enterprise. This leads to many of these biotech 
firms being funded by scientists most of whom are university professors and quite a few of 
them remain as faculty. In Catalonia, 56% of the pure biotech companies have been funded by 
scientists.
4 Actually, biotech start-ups are typically spin-off companies based on innovative 
products or processes resulting from discoveries within academic research. 
Biotechnology contributes about 2 percent of the EU gross value added. However, it is still an 
emerging industry consisting of a few, very large companies and many very small ones. The 
average number of workers in a Catalan biotech firm in 2007 was 17,
5 while in Europe it was 
24 and in the United States it was 90.
6 The biotechnology industry started in the United States 
and from there it spread throughout the globe. However, the distance from other countries with 
respect to the United States is still very substantial. There is now clear evidence of a maturation 
of the United States biotech industry, with strong pipelines and robust revenue growth, while 
Canada and Europe are progressively catching up. In 2004, 78 percent of the biotech industry 
revenues came from the United States while only 14 percent of them were originated in Europe
7 
(see Figure 1). 
                                              
4 CataloniaBio Survey, 2005. 
5 Genoma. 
6 Ernst & Young 2007 global biotechnology report “Beyond Borders”. 
7 Ernst & Young 2005 global biotechnology report.  
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Figure 1 












1.1. Industry History 
A milestone marks the beginning of modern biotechnology: in 1953 Watson and Crick 
published a short article in “Nature” revealing the DNA structure. It took 20 years for Cohen 
and Boyer to perform the first successful recombinant DNA experiment, which allowed 
scientists to isolate specific genes. And it took yet another 7 years for biotechnology to 
establish itself as a possible business with the Genentech IPO. This marked the beginning of the 
first biotech wave. The commercial potential of the discovery and its successful IPO in 1980 
created an enormous stimulus for other new entrants. Like Genentech, the new firms were 
typically founded by scientists from leading United States universities. The new entrants 
maintained extremely good links with universities, often licensing some of the basic technology 


























4 -  IESE Business School-University of Navarra 
Table 1 
Modern Biotechnology Timeline 
  2006:  Nobel Prize for the discovery of RNA interference 
    Opening of the Barcelona Biomedical Research Park (PRBB) 
 2004:  Catalan Bioregió is constituted 
 2003:  Completition of the sequancing of the human genome 
 2002:  CIDEM-PCB bioincubator 
 2001:  Opening of Barcelona’s Scientific Park (PCB) 
  Advancell is founded 
  2000:  Center for Genomic Regulation is created 
  Oryzon Genomics is founded 
  1998:  First biotech drug (neupogen) to achieve blockbuster status 
    Discovery of the RNA interference 
  1997:  First cloned animal (Dolly) 
  1994:  Approval for a whole food produced through biotechnology 
  1990:  Human gene therapy is attempted successfully 
    Human Genome Project begins 
  1986:  First biotech cancer drug is produced (Interferon) 
    Genetically engineered plants (tobacco) are grown in field trials 
  1984:  Development of the PCR (polymerase chain reaction), that allows to amplify very small 
    amounts of genetic material 
  1980:  First biotech IPO (Genentech) 
    Bayh-Doyle Act: allows universities and faculty to stake patent claims on discoveries 
  1978:  Biogen, first European biotech founded 
  1976:  The technology of producing monocional antibodies is developed (Milstein & Kohler) 
   Genentech  Founded 
  1953:  Watson and Crick reveal the three-dimensional structure of DNA 
 
1.2. Red Biotech (Biotechnology Applied to Health) 
When it comes to biotechnology, red biotech is generally dominant. In the United States it 
represents 65 percent of all its biotech companies and 74 percent of all its employees. In 
Europe, the healthcare sector includes 55 percent of all the European biotech companies and it 
employs 65 percent of its workers.
8 This is also the case in Catalonia, where more than two 
thirds of the firms contribute to the health, medical and diagnostics sectors. Out of those, 
70 percent are dedicated to the development of new drugs and 25 percent to diagnosis.
9  
There is no doubt that biotechnology has tremendous potential in this sector where, for several 
years in a row, biotech companies have secured more approvals than their big pharma 
counterparts.
10 A report to the European Commission
11 pointed out that, in 2006, biotechnology 
already contributed to 5 percent of the GVA of the European pharmaceutical market. 
                                              
8 Europabio, 2006. 
9 INE, “Encuesta sobre innovación tecnológica de las empresas” (Survey of companies’ technological innovation), 
2006. 
10 Ernst & Young, 2007. 
11 See reference for European Commission (2007).  
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However, uncertainty still remains high. Statistics show that the probability of success of a new 
molecule that starts being developed (after several years in the discovery process) is only 
1 percent. Hence, products that appear promising in the development phase might fail to reach 
later stages or be commercialized at all. Moreover, the process from the identification of a 
molecule to the marketing of a pharmaceutical based on it takes about 20 years. 
The Figure 2 represents the value chain of red biotech for drug development and it includes the 
corresponding timeline for Catalonia: 
 
Figure 2 








Technological uncertainty and a long time lines to reach the final market are the two main 
characteristics of red biotech and the ones that will most seriously condition its successful 
development.  
The main attraction of red biotech lies in the fact that it may eventually lead to the discovery 
and development of a new product that might have been very hard or impossible to obtain with 
the classical pharmaceutical methods. If this new product is different enough from the existing 
ones and if it affects a sizeable amount of patients, this biopharma could become one of the key 
players in the pharmaceutical industry and make very substantial profits. 
The current top biotechnology firms dedicated to the healthcare sector can be distinguished 
between product-oriented and platform-oriented firms. The first set of companies focuses on 
the discovery, development, production and commercialization of products. Amgen, Genentech 
or Genzyme are examples of this group of firms. The second group includes firms dedicated to 
the development and commercialization of new technologies and devices used in the discovery 
and development phases. Quest Diagnostics or Applera Corporation are examples of major 
platform-oriented red biotech firms. 
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Table 2 
Ranking of Biopharma Companies (in revenue) in 2006 
 
  TOP 10 Blotech companies by 2006 revenues (USD Millions) 
 
             Net 
       Date  of      income/ 
Rank Company  Country  Incorporation  Revenues  R&D  (loss)  Employees 
 
 
  1 Amgen  United  States  1980  14,268  3,366    2,950  20,000 
 2  Genentech  United  States  1976  9,284  1,773  2,113  10,533 
  3  Quest Diagnostics  United States  1969*  6,269  -  586  41,000 
 4  Genzyme  United  States  1981  3,187  650  -17  9,000 
 5  UCB  Belgium  1928*    3,328  811  484  8,477 
  6  Gilead Sciences  United States  1987  3,026  384  -1,190  2,515 
 
 7  Serono  Switzerland  1906*    2,827  560  735  4,775 
 
  8  Biogen Idec  United States  1985  2,683  718  217  3,750 
 
 9  CSL  Australia  1916*  2,079  117  256  7,575 
   Applena 
 10 Corporation  United  States  1937*  1,949**  ---  212  5,830 
  
 
*Originally not biotech. 
**Fiscal Year-End: June. 
Source: Author’s elaboration – Orbis. Hoovers. 
1.3. White Biotech (Industry) 
White biotechnology refers to the application of biotechnological methods and processes for the 
production of chemicals, materials and energy or the optimization of industrial processes. 
Europe is a key world player in white biotech, boasting, for instance, 75 percent of all the 
enzyme production in the world. The larger producers of modern white biotechnology goods 
and services are precisely enzyme producers, with top market players like the Danish firms 
Novozymes and Danisco’s Genencor Int’l, which in 2007 had 44 and 21 percent of the world 
enzyme market share, respectively.
12  
A report to the European Commission (2007) already pointed out that industrial biotechnology 
contributed 5.85 percent of the European GVA. However, only 15 percent of the Catalan 
biotech firms are dedicated to industrial biotechnology.
13  
White biotechnology is used nowadays to manufacture a wide range of products and it can 
intervene at every stage of the manufacturing process as Figure 3 shows.  
 
                                              
12 Novozymes Annual Report 2007. 
13 Genoma, 2007.  
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Figure 3 












White biotechnology has a much shorter timeline than red; a new product or technological 
solution can reach the market in about 2 years. However, so far, the role of these firms has been 
more an auxiliary one, facilitating or accelerating an already existing industrial process and 
hence their potential of becoming a top player in the chemical or industrial market is more 
doubtful. 
 
1.4. Green Biotech (Agrofood) 
We can distinguish two main kinds of green biotech: first, these technologies devoted directly 
to agriculture. Some examples would be the in vitro technique that allows for the rapid growth 
of whole plants from minute parts of plants, the development of molecular markers that allow 
the selection of desirable traits in a plant such as its resistance to some plagues, and, also, 
genetic engineering of plants that lead to the production of new types of genetically modified 
crops. The second type of green biotech are technologies that are applied directly to the food 
industry, and they range from the development of nutraceuticals (new foods that claim to have 
health benefits) to new techniques that facilitate the inclusion of supplements to the food 
industry. Major companies, by 2007 revenues, operating in the green biotech market include 
Syngenta AG (€6,329m), Monsanto Company (€5,865m), BASF SE’s Agricultural Products and 
Nutrition division (€4,989m), DuPont’s Agriculture & Nutrition division (€4,658m), Bayer 
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Figure 4 












In 2006, 11 percent of the biotechnology companies in Europe were dedicated to green biotech, 
5 percent in the United States, and 12 percent in Catalonia. 
Even though biotechnology could potentially be applied in many stages of the food value 
chain, it is currently mainly applied in the sectors providing inputs to primary production 
(propagation of plants and animals, breeding, etc.). In Europe, biotechnology is used in the 
production of about 20 percent of the European agro-food sector output.
15 
2. Biotechnology in Catalonia 
2.1. Activity 
Catalonia is a key player in the Spanish biotechnology market. According to Asebio, in 
2006, Catalonia was the Spanish region that created the most new biotech firms (30 percent of the 
total). Today, Catalonia accounts for 35 percent of the Spanish R&D expenditure in biotechnology 
and is home to 24 percent of Spanish biotech firms. Of the firms fully dedicated to biotechnology, 
Catalonia hosts 41 of the 221 that are located in the Spanish territory (see Figures 5.a and 5.b). 
About 65 percent of the Catalan firms fully dedicated to biotechnology are devoted to health 
and diagnostic activities. This corresponds to the same share of biotechnology firms dedicated 
to the medical sector as the United States, but is slightly higher than the European 55 percent. 
Such a high concentration in red biotechnology is less surprising if we take into account that 
the fine chemical sector represents 2.3 percent of the Catalan GDP and that more than 70 percent of 
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the sector in Spain is found in Catalonia. However, Catalonia also has a very strong chemical sector 
that produces 43 percent of the Spanish value added and only a very small proportion of the 
biotechnology is dedicated to white biotechnology, as Figure 6 shows. 
 
Figure 5.a 
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Figure 6 
Biotech Activity in Catalonia 
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  Source: Author from Genoma data. 
2.2. Size 
Even though Catalonia is clearly a prominent player in the Spanish biotechnology market, its 
firms are quite small. In 2003 there were only 27 firms that had biotechnology as their core 
business, with an average of six workers. As Figure 7 shows, they were also small and few 
compared to the size and number of firms in other bioclusters. However, both the number of 
firms and their size have experienced spectacular growth and, by 2007, there were already 
41 firms fully dedicated to biotechnology, with an average of 17 workers (Genoma). In spite 
of this, Catalan biotechnology firm size is still below the American (90 workers) or the 
European (24 workers) average.
16  
This fact is also true if we compare the Catalan bioregion with other European biotechnology 
clusters (Figure 7), and especially true if we compare the size and number of biotech firms in 
Catalonia with that of two top bioclusters in the United States, both of which are home to more 
than 200 firms. 
The United States biotechnology sector is clearly much larger and more mature than the 
European one and, hence, the United States biotechnology firms have characteristics and needs 
that could be quite different from those of Catalan biotech. Given the important differences 
between the United States and Europe, from now on we will focus our analysis of the position 
of the Catalan biocluster in the European context, since it is a better benchmark for comparison 
for Catalonia. 
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Figure 7 










  Source: Boston Consulting Group, 2003 and Genoma. 
  Data 2005, NetBioClue. Oxford 2007, OBN Biocluster 
  Report 2008, Oxfordshire Bioscience Cluster Report. 
 
 
In the last few years, as the existing firms become more mature, the turnover of Catalan firms 
has also increased significantly, confirming that the sector is becoming more and more 
dynamic (Figure 8).  
 
Figure 8 
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2.3. Quantifying the Potential Impact of Catalan Biotech in the Catalan Economy 
In order to determine the potential impact of biotechnology on the Catalan economy, we follow 
the same methodology as the “Bio4EU Draft Final Analysis report”
17 (henceforth, “Bio4”) from 
the European Commission. We consider all the economic sectors with biotechnology 
implications as those that are users of biotechnology techniques and those that are users of 
biotechnology-derived products. For each of these sectors (previously determined in the Bio4 
report) we consider their contribution to Catalonia and the employment they generate. 
Data used is from Idescat.
18 Due to data availability, we used year 2006 for industrial and 
agriculture sectors and 2005 for services. Moreover, we have collected data from 2001 in order 
to see the time evolution of the biotechnological related sectors. The only exception here is the 
service sector “Technical testing and analysis” where 2002 was the closest data available. 
The identification of the relevant sectors in which biotechnology can have an impact comes 
from Bio4 in the framework of the NACE
19 classification where feasible. The Catalan economic 
sectors classification used in Catalonia (called CCAE
20) completely matches the NACE 
classification, so the equivalence by code number was easy. 
Our results (detailed in Appendix A) indicate that the Catalan biotechnology sector has the 
potential to affect sectors that represent 10 percent of the Catalan GDP such as healthcare, 
pharma, the chemical industry, etc. These sectors currently employ 9.3 percent of the Catalan 
workforce (see Annex A for calculations).  
2.4. Scientific Production and Quality 
Basic scientific research has a strategic importance for the future survival of the Catalan 
biotechnology sector. In this respect, Spain has a clear advantage since, according to Genoma, 
it has been the fourth major publisher in biotechnology and microbiology in Europe after 
Germany, United Kingdom and France for the period 2000-2006. In 2007 Spain was the fifth 
contributor in the EU-15 in molecular biotechnology research just behind United Kingdom, 
Germany, France and Italy. 
Given the crucial importance of research in this industry it is not surprising that, in 2003, 
68 percent of the Catalan biotech firms had more than half of their workers dedicated to R&D.
21 
                                              
17 “Contributions of modern biotechnology to European policy objectives,” Draft Final – VERSION 31 
January 2007 for the European Commission. 
18 Idescat does not provide data for Veterinary activities, so we have used market studies. In other cases, 
where the disaggregation has been impossible, we have taken an aggregated sector, e.g., agriculture and 
fishing instead of breeding and seeds. This data was obtained from “L’aportació del sector sanitari a 
l’economia catalana” from Estudis Caixa Catalunya. 
19 NACE is the statistical classification of economic activities in the European Community. In the 
Reference report, version 1.1 of 2002 is used. 
20 In our report the CCAE-93 Rev.1 is used. 
21 CataloniaBio survey, 2005.  
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This proportion is clearly higher than the European 47 percent average.
22 Figure 9 compares the 
number of scientific publications of several European bioclusters. Here we can see that 
Catalonia started from a very low position, but in the last three years it has been able to 
significantly reduce the gap with respect to the other European bioclusters. However, the impact 
of the Catalan publications is still low (Figure 10) even though it has also been improving. 
 
Figure 9 
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As we have already mentioned, the chemicals sector is quite strong in Catalonia; Catalan 
chemical companies produce 43 percent of the total Spanish value added. However, its 
importance is not mapped into the weight of the white biotechnology, which represents only 
about 12 percent of the whole Catalan biotech. 
 
Figure 11 












Catalonia Oxford Cambridge Boston San Francisco Flanders
 
Source: Author, Using ISI – Thomson web of knowledge data. 
 
Figure 11 shows the evolution of Catalan publications in biochemistry. In this sector, the 
improvement with respect to other European bioclusters had already started in 2001, and now 
Catalonia’s scientific production in biochemistry is already above that of the Oxford and 
Flanders biotechnology clusters. Unfortunately, the ISI data does not allow us to weight the 
importance of the number of publications by their impact, as we have done in Figure 10. 
However, these results are clouded by the patent data. On this front, both Catalonia and Spain 
lie way behind other biotechnology clusters. According to Genoma, Spain is at the bottom of 
the European ranking for patent acceptances (number 11
th in the U-15) and only number 9
th in 
the number of patent applications. In 2007, 30 Catalan Companies registered 54 patents either 
through the OEPM (Spanish patents agency), the EPO (European), the USPTO (in the United 
States) or, in most cases, the PCT (international patents). The total number of registered patents 
in Spain was 137 (Asebio). On the positive side, this represents a significant improvement in the 
last four years, given that the number of biotechnology patent applications in 2003 was only 
66.
23 
2.5. Product pipeline 
In 2007, 64 new products developed by Spanish companies were launched onto the market. Of 
those, ten were launched by Catalan companies (Appendix B, Table B.1.). Catalonia currently 
                                              
23 Eurostat, Patent statistics.  
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has 29 products in different stages of the development pipeline (Figure 12). As expected, the 
pipeline has the textbook funnel shape, continuously declining as we move up to later phases. 
 
Figure 12 








Source: Author, based on Asebio’s Spanish Red Biotechnology Pipeline. March 2008. 
 
Table 3 compares the stage of the Catalan and Spanish biotechnology pipeline with that of 
other European areas. Due to data restrictions, Data for Table 2 comes from two different 
sources: the data for Spain and Catalonia is from Asebio while data for the rest of Europe 
comes from Ernst & Young 2008 Report. This could explain the fact that the numbers for Spain 
look high compared to those for the rest of Europe; even more so if we take into account that, 
in their report, Spain was ranked number 10 out of 16 European countries. Given these 
discrepancies, we will focus our analysis not on the absolute numbers, but on the pipeline 
structure. It is interesting to notice that the United Kingdom, which has two very mature 
biotechnology clusters (Cambridge and Oxford) has only 39 percent of its products in the 
preclinical stage, while this number jumps up to 65 percent for Catalonia but only 45 percent 
for Spain as a whole. Products in phase III, on the other hand, represent 10 percent of the 
United Kingdom pipeline, while they are only 8 and 7 percent for Spain and Catalonia, 
respectively. 
In terms of the nature of compounds being pursued, the Catalan pipeline is more diversified 
across the different therapeutic areas than the Spanish one, which is mostly focused in 
oncology (see Figure 13). This last one is more in sync with the observed European tendencies, 
where the top three therapeutic areas are oncology (28%), neurology (15%) and infectious 
diseases (13%).
24  
                                              
24 Ernst & Young (2008).  
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Table 3 
Red Biotech Pipeline in Europe, 2007 
 
  Preclinical  Phase I  Phase II  Phase III  Total 
United Kingdom  140 66  119 36  361 
Germany  133 39 73 17  262 
Denmark  65 46 60 17  188 
Belgium  19  12 9 3  43 
Netherlands  23 11 13  4 51 
Spain  134 74 62 24  294 
Catalonia  19 6 2 2  29 
Source: Ernst & Young Global biotechnology report 2008. * Data for Spain and Catalonia is from Asebio. 
 
Figure 13 










2.6.  Funding 
Since biotechnology is still an emerging sector in Spain, and in most of the other countries, 
public funding plays a very important role. In 2004, in Spain, 70 percent of all R&D 
expenditures in biotechnology were publicly funded. This was, for instance, slightly below the 
75 percent public share of Norway. 
In 2007, 80 percent of public funding was devoted to R&D in Spain (Asebio 2007). Table 4 
shows the evolution of R&D spending in biotechnology for Catalonia and Spain. In the period 
2000-2006 this grew by 450 and 400 percent respectively. In 2006, 374 million Euros came 
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Table 4 
R&D Investment in Biotechnology (in million €) 
  2000  2001  2002  2003  2004  2005  2006 
Catalonia  5.82  7.98  11.57  16.35  25.12  28.07  32.08 
Spain  85.44  117.88  167.96  221.83  271.18  322.75  422.00 
Source: Genoma. 
 
As is the case in many emerging sectors, biotechnology firms have to find new forms of 
funding. Venture capital has been of key importance, for instance in the development of the 
biotechnology industry in the United States which, in 2007, still boasted 72 percent of all 
the venture capital investments worldwide. However, the importance of venture capital in Spain 
is growing steadily. In 2007, Suan Biotech was constituted and in 2008 YSIOS just closed the 
largest Spanish venture capital fund completely dedicated to biotechnology. 
Table 5 provides data on venture capital investment for several countries. The United States is 
clearly far ahead, but within Europe, Spain is gaining momentum and actually, venture capital 
investment for the period 2000-2006 grew a 205 percent. Moreover, in 2007, 17 Catalan 
biotechnology companies participated in financial operations considered by Asebio to be 
among the most important in the Spanish biotechnology sector in 2007. CDTI’s Neotec 
participated in five of those operations and another set of investors participated in nine capital 
increases that brought the biotechnology firms an overall 14.9 m€ investment (Table 5). Also, 
eight Catalan biotechnology companies established a total of 24 partnerships 26% of which 
were established with non Spanish players (Asebio). 
 
Table 5 





Kingdom  Germany Denmark  Belgium  Netherlands  Spain 
2000 3,428  261.1  431.6  88.6  73.6  11.9  4.9 
2003 1,948  250.6  171.3  42.1  26.1  17.5  3.6 
2006 3,823  238  213  144  118  29  14.9 
Source: Biocentury (2000 and 2003) and Ernst&Young (2006)/ own elaboration. 
3. Competitive Strengths and Weaknesses 
After briefly presenting the main characteristics of the Catalan biotechnology industry in the 
previous section, our purpose here is to evaluate the competitive position of Catalonia in six 
aspects that play a crucial role for the development of a biocluster and that were first pointed 
out by the Lord Sainsbury´s Report on biotechnology (1999).  
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3.1.  Strong Science Base 
Leading edge science and a critical mass of research activity provide the lifeblood of biotech 
clusters. In this aspect, as we have seen in the previous chapter, Catalonia is still behind the 
research production of the top European bioclusters but is quickly catching up, especially 
regarding white biotechnology. Spanish research publications in biotechnology grew 27.3 
percent from 2000-2006, while the average growth for the EU-15 was 4 percent.
25 
The distance from Europe regarding patents is more important but it is also diminishing. Figure 
14 shows the progress in the number of biotechnology patents obtained in Spain. 
 
Figure 14 











Finally, Catalonia is home to an extensive network of public and private research institutes. The 
Catalan Science and Research Network includes 12 universities, 9 research centers, 6 research 
hospitals, 6 Science parks and numerous R&D departments of private firms. 
3.2.  Entrepreneurial culture 
Entrepreneurship is often considered an important factor in explaining the differences in the 
rate of technical progress between countries. Its role is of particular importance for the 
development and growth of biotechnology since it is still not a mature industry in Catalonia (or 
in Europe in general). Moreover, a strong entrepreneurial culture will help ease the transition 
from scientific research to a final commercial product. Entrepreneurship will also offer 
opportunities to young scientists, providing them with a platform to take their basic research to 
the next level. 
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However, measuring the entrepreneurship culture of a country or region is complex since there 
are many determinants of this practice such as national culture, legal environment, public 
sector size, etc. Many institutions attempt to measure it by conducting surveys of the 
population or of CEOs. Here we present the results of two of these surveys, which are the most 
commonly cited in business. The Global Entrepreneurship Monitor (GEM), for instance, assigned 
Catalonia an entrepreneurship index of 8.57% in 2006, above the averages of Spain (7.27%); 
the United Kingdom (5.77%) and Germany (4.21%). On the other hand, the Department of 
Economic Development of Dubai (DED) conducted an Executive Opinion Survey for about 200 
Chief Executive Officers (CEOs) of major Dubai-based organizations in 2005, following the 
structure of the World Competitiveness report of IMD and including countries and sub-national 
regions. The next table shows the results of that survey for a selected number of countries, in 




   Entrepreneurship 
Ease of doing 
business Firms  Creation 
          
Switzerland 6.11  7.14  6.88 
Belgium 5.97  5.30  5.17 
France 5.29  4.88  4.7 
Germany 4.97  4.64  4.97 
Catalonia 4.91 5.56 5.20 
Spain 4.91  5.48  5.18 
United Kingdom  4.88  5.98  5.76 
Scotland 4.26  6.05  5.16 
Source: Dubai's competitiveness advantage study. Legend: Entrepreneurship (10 - widespread in a country; 0 - not 
widespread in a country). Ease of doing business (10 - is a competitive advantage in the country; 0 - is not a competitive 
advantage in the country). Creation of firms (10 - supported by legislation in the country; 0 - hindered by legislation in the 
country). 
3.3. Growing Company Base and Large Related Firms 
Biotechnology Company Base 
Having a critical mass helps to attract other companies, suppliers, investors and skilled labor to 
the biocluster. Moreover, as we have already seen, biotechnology can contribute to very many 
different stages of the value chain of the pharmaceutical, chemical and food and beverage 
production process. Hence, having a large surrounding base of companies (pharmaceutical, 
chemical, food and beverages, etc.) that could generate strong demand for the first stages of a 
new biotech technology is also of great importance to be able to develop biotechnology as a 
business. Proximity to large companies in industries related to biotechnology can also 
contribute to providing management expertise and partnering opportunities. 
Even though the number of companies in the Catalan biocluster is still small compared to other 
European clusters (Figure 7), it has been growing steadily. Between 2004 and 2007 it grew 
51 percent, while in Spain the overall growth rate of biotechnology firms was 32 percent and,  
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in Munich and Cambridge it was 36 percent. The turnover and number of employees of these 
companies have also been gradually increasing (Figure 8). 
Large Related Industries 
Apart from the number of pure biotechnology firms, one should also consider the importance of 
the existing base of industries that could generate demand for the different biotechnologies at 
several stages of their production process. In this respect, Catalonia accounts for roughly 23, 40 
and 70 percent of Spain’s total food, chemical and fine pharmaceutical chemical production, 
respectively. Because 65 percent of the Catalan biotechnology firms concentrate on red biotech, 
the pharmaceutical sector is one of the axes of the Catalan biocluster. Catalonia hosts 163 of 
the 377 pharmaceutical companies in Spain (Farmaindustria) and 66 percent of the Spanish fine 
chemical companies (Cidem).  
Both the local and international pharmaceutical companies based in Barcelona account for 56% 
of the R&D expenditure in the Spanish pharmaceutical sector, but we should note that the 
Spanish R&D expenditure level (approximately 4.2% of turnover) is below the EU average of 
15 percent (SPRI). This difference can be attributed to the facts that: a) it is a common practice 
for the multinationals to centralize the R&D at their corporate headquarters while conducting 
production activities abroad, and b) the limited size of Spanish pharmaceuticals in comparison 
to larger multinational leaders that play very important roles in other European reference 
bioclusters. For instance, Biovalley counts on the presence of Novartis and Roche amongst 
others. 
Catalonia also hosts 38 percent of the Spanish medical device companies, among which we find 
manufacturers (with their own product or not), distributors, marketers and specialized services 
companies, segmented in a wide range of specialties (SPRI). 
3.4. Ability to Attract Key Staff 
According to Asebio´s 2007 Survey, the most relevant factors currently facilitating the proper 
development of the biotechnology industry in Spain are the worker’s skills, the easy access to 
qualified staff and the improvement of cooperation with universities and Technology Centers. 
In order to succeed and to become a mature sector, biotechnology companies have to be able to 
attract the best management and scientific staff, competing with other countries and 
companies. Moreover, abundant and qualified research is a necessary condition not only to 
advance in cutting-edge science but also to attract and sustain investments by public and 
private entities. Clusters can facilitate this aspect by providing a scientific environment and 
offering a wide range of career opportunities in the field. Quality of life, being in a vibrant 
international city and remuneration are also keys to attracting strategic staff. According to the 
European Cities Monitor survey, Barcelona was the European city with the best quality of life 
for workers in 2006 and it has held this position for the last seven years. 
On the other hand, the average remuneration in 2006 for researchers in Spain, €38,873, PPP 
adjusted, was slightly below the EU 25 average of €40,126 (PPP adjusted) and far lower than 
the United Kingdom average (€52,776, PPP adjusted) and Germany (€53,358, PPP adjusted). 
Finally, in order to attract key management, the size of related firms such as pharmaceutical or 
chemical is also important because some of the biotechnology managers could come from the  
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related industries, as has been the case in the United States and the Unites Kingdom. In this 
aspect, the size of Catalan firms is generally smaller than that of their European counterparts.  
3.5. Availability of Funding 
As is the case in many developing industries, access to funding is essential for the development 
and establishment of biotechnology as a business. The funding challenge becomes especially 
important in the case of biopharma, given its two key characteristics: a lot of uncertainty and 
long-term investment. 
Spain ranked only 43 in the 2007 Capital Access Index,
26 which ranks countries around the 
world in terms of the financial infrastructures that support entrepreneurial activity by providing 
access to capital. The United Kingdom ranked 2nd and Germany 17
th. 
Public funding for R&D project plays a very important role (see Section 2.6 of this document). 
In Spain, it has mostly facilitated the development and growth of basic research and also in the 
creation of new infrastructures (Parques Tecnológicos). Moreover, in Spain there are public 
entities like the Center for the Development of Industrial Tecnology (CDTI), which has the 
objective of facilitating the creation of new technological firms, such as biotechnology ones. 
CDTI has two different tools to achieve this goal. First, to address the capital needs of recently 
created technological firms, it provides the NEOTEC program, which facilitates access to a 
maximum of €600,000 of seed capital. Second, through the NEOTEC CONSOLIDACION Program, 
to facilitate access to capital for biotech firms that are in the consolidation process. The 
maximum amount available is €1 million for firms younger than six years old.  
Informal individual investors or business angels also intervene in the starting process of a firm. 
Business angel networks bring together angels and increase the efficiency and likelihood of 
matching angels and suitable entrepreneurs. In 2006, of a total of 211 networks identified in Europe 
by the EBAN (European Business Angel Network), Spain had 21, of which 8 were in Catalonia; by 
comparison, France had 35, Germany 41 and the United Kingdom 34. In 2004, Spain hosted 291 
individual business angels, well below the 829 of Germany or 8,240 of the United Kingdom. 
In 2005, BCN Ventures, a public-private fund, was constituted with the objective of investing in 
Spanish biotechnology firms. 
As we have already pointed out (Table 5), there is still a big distance between Europe and the United 
States regarding the role of Venture Capital in general and in biotechnology in particular, with the 
United States receiving 72 percent of all the worldwide investments. However, access to venture 
capital is quickly improving for Catalan firms; for instance, two major companies were recently 
constituted: Suan Biotech (€30 million) and YSIOS (€70 million). 
Another available option for the biotech firms that has not been used yet, is their possibility of 
accessing the Spanish Alternative Stock Market (MAB), which was constituted in 2005 with the 
objective of facilitating access to capital. Initially this was only to Venture Capital and 
SICAVs,
27 but since 2007 also to smaller firms. However, so far, even though several of the 
                                              
26 Milken Institute Capital access Index 2007. 
27 SICAV “société d'investissement à capital variable” - investment company with variable capital.  
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biotechnology firms we have talked to have shown interest in the MAB, none of them has used 
it yet. When asked why, they have mostly mentioned the current economic cycle. 
Hence, it seems that in Catalonia access to initial capital, at least for the first three years and for the 
most basic research stages, is quite readily available. However, finding investors in the next steps of 
the value chain is proving to be more of a challenge. After several interviews with experts in the 
sector, we believe that there are two main reasons for this. One is that in Spain, and in Catalonia in 
particular, the potential investor base is not yet used to investing in such long risky projects. They 
are more used to thinking about traditional investments where the investment is based on a final 
product. In biotechnology, most of the investment should be thought of as an investment in 
expectations. The second reason is that access to international capital is not easy, especially at the 
beginning of the process. In this aspect there are already two alternative stock markets for smaller 
firms in Europe: AIM in the United Kingdom and Alternext in France. Considering participation in 
the MAB has pros and cons, therefore: on the one hand it is easier for smaller Spanish firms to be in 
the Spanish MAB than in the other foreign ones. However, on the other hand, the two existing 
markets already have an investor base used to providing capital to this type of projects. Plus, it 
might facilitate access of the firm to international investors.  
According to Asebio’s 2007 Survey, access to finance is still one of the major causes of concern 
for the biotechnology professionals concerning the proper development of the sector. This is 
particularly true for those firms that have already been in existence for several years. For them, 
access to public funds to start a business is no longer available and they are now facing the 
possible need of substantial financial injections in order for them to be able to continue to the 
next phase. In fact, in its Critical I report, Europabio already warned European biotech firms 
about the “finance precipice” they were facing after 7-10 years of existence. This situation 
might be particularly challenging in the current “credit crunch” economic environment. 
3.6. Premises and Infrastructures 
General infrastructure resources give us an ambiguous result about the situation of Catalonia in 
comparison to other European regions: 
Catalonia is well provided for in highway infrastructures, with resources that are 20.2% above 
the 25 European richest regions average,
28 but Catalonia is 46% below in railway resources. In 
relation to Spain, Catalonia is below the average of infrastructure stock per inhabitant. The 
Catalan capital stock per inhabitant in roads, airports and harbors is only 88, 57, and 93 
percent respectively of the Spanish average per inhabitant.
29 Catalonia is only above the 
Spanish average capital stock per inhabitant in railways (116 percent). 
However, Barcelona is well placed regarding the availability of office space and technology 
parks, which play a very important role in biotechnology (Table 7). Taking into account the 
closest main cities to the European bioclusters, Barcelona ranked 2
nd in office space in Europe 
just below London (the closest main city to Oxford and Cambridge).
30  
                                              
28 Measured by F index. See “Dotacions d’infraestructura l’opció de diferents models territorials.” 
29 Institut Valencià d´Investigacions Econòmiques. 
30 European Cities Monitor, 2007. Cushman & Wakefield Healey & Baker.  
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The Network of Science and Technology Parks of Catalonia (Xarxa de Parcs Científics i 
Tecnològics de Catalunya - XPCAT) contains big spaces of production, transfer, diffusion and 
use of knowledge. It consists of centers and groups for university research, technological 
centers, large companies and their associate R&D centers, companies focusing on innovation as 
well as new knowledge-based companies. It includes 15 Science & Technological Parks, mainly 
concentrated in the Barcelona area, of which three are specifically dedicated to biomedicine and 








   Research 





Aarhus  Denmark  29  4  1    2 
Atlantic biotherapies  France  31  7  1    2 
Biodundee  United Kingdom  16  4  5    4 
Region Munich  Germany  170  6  2    3 
Umea  Sweden  26  3  1    2 
Biovalley 
Germany/France/ 
Switzerland  30  6   12 
biotechvalley.nu  Sweden  16  3  3    1 
Cambridge United  Kingdom  422  13  1 13 
Ile de grance  France     29  4  12 
Grenoble alpes  France  14  14  1    3 
Heidelberg  Germany  121  8  4    3 
MI-TO Italy  114  25  4    6 
Szeged neurobiologic.  Hungary  7  3       0 
Uppsala Sweden  37  6  1    2 
Vaccione therapy  Hungary  3  4  0    0 
Catalonia Spain  41  15  1    6 
Source: Netbioclue, Dos and don'ts for biotech cluster development / author. 
4. Conclusions 
Biotechnology is rapidly gaining priority in many countries as a key engine for long-term 
economic growth. This is also the case of Catalonia, which now has the largest share (23.7 
percent) of firms with activities related to biotechnology in Spain (Asebio, 2007). 
There is no doubt of the relevance of Catalan biotechnology within the Spanish context. 
However, in order to be able to evaluate the Catalan competitive strengths and weaknesses in 
biotechnology, one should take a more international perspective and compare the position of 
Catalonia to that of other biotechnology regions. In the international context the United States 
is clearly the leader, with an already maturing biotechnology sector and, hence, with firms that 
have quite different characteristics and needs from the Catalan ones, which are only in the 
early stages of the development of the sector. Because of this, when looking at the competitive 
position of the Catalan biotechnology, we have focused on the comparison of Catalonia with 
                                              
31 Xarxa de Parcs Científics i Tecnològics de Catalunya - XPCAT web.  
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the most active European bioclusters (Munich, Oxford, Cambridge) as well as with some more 
recent ones (Flanders). 
We can conclude the following: first, the biotechnology sector in Catalonia is still small by 
European standards, with an average of only 17 workers per firm and only 41 pure biotech 
companies. However, it is quickly catching up. In 2006, for instance, Catalonia was the most 
dynamic Spanish region in biotechnology. 
Second, the Catalan effort in research has been improving steadily and, for some disciplines 
such as biochemistry, it has overcome the position of other European biotechnology regions. 
However, in patents and licensing, the distance from Europe remains still very high. 
Third, red biotech accounts for more than two thirds of the Catalan biotechnology firms. This is 
not so surprising if we take into account the fact that more than 70 percent of the Spanish fine 
pharmaceutical production is located in Catalonia. However, Catalonia also boasts 40 percent of 
all the chemical production in Spain and only 12 percent of the Catalan biotech firms are 
devoted to white biotechnology. 
Fourth, one of the main advantages of the Catalan biocluster relies on the attractiveness of 
Barcelona to draw key staff (having been ranked as the business city with the best quality of 
life in Europe. However, researcher salaries are still below the European average). 
Fifth, access to funding still remains an important challenge for the Catalan biotechnology 
firms. Part of this could be due to the following two facts: the average size of the related 
industries is relatively small compared to the size of industries hosted in other European 
biotechnology clusters. These firms are the ones that have the capacity to generate demand for 
biotechnology in several intermediate stages of the value chain production process and such a 
demand is eased by proximity. The second fact is that the potential investors are not familiar 
with this type of investment (high uncertainty and long value chains). However, this last aspect 
has considerably improved recently with the constitution of several Spanish venture capital 
firms exclusively focused on biotechnology.  
Sixth, the main challenge now is to find funding sources for those firms that have already been 
in the market for a while and which could be facing a “finance precipice”. This is particularly 
true in the current economic environment. 
Given this evaluation, we propose the following three policy recommendations: 
First, policy should focus on providing the right incentives to promote quality research and on 
facilitating the implementation of such research into a business model, regardless of the 
particular sector it involves.  
Second, policy should help foster management and staff mobility. The size of related firms from 
which biotechnology could attract managers is quite small in Catalonia, compared to European 
ones. Biotechnology firms might need to look outside, not only for managers, but also to attract 
key researchers. Staff mobility from one biocluster to another also has the additional advantage 
of potentially helping attract more international capital. Catalonia could, in this way, obtain 
managers that have experience abroad and that might already have a track record of attracting 
foreign venture capital. 
Third, policy should contribute to fostering the understanding of the biotechnology sector as 
another way of helping to attract investors. The Catalan biotechnology sector needs to be  
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creative in finding ways to attract not only foreign but also national capital. One way is to 
facilitate the understanding of the sector characteristics amongst potential investors: long 
timelines, high uncertainty but also high potential. Moreover, often, when one invests in 
biotechnology, the investment is not on the development of a final product but on achieving 
the next step in the value chain (i.e., reaching phase I of the clinical trial) and hence, the 
relevant timeline for the investment might end up being shorter than initially expected. 
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Appendix B 



























Source: Asebio. Annual Report 2007. Selected companies are Author’s selection based on the head offices location. 
 
In United States and United Kingdom, the currency symbol goes before the quantity. Therefore, 
Table B.2, last column “Investment (m€)” – should read “Investment (€m).” 
Also, last line should read “head office location”, not “head offices.” 
 
  Products & Services launched to market in 2007 by Catalan Companies 
Company  Product  Type 
Advancell  Evaluation of substances subject to the REACH normative  Research Service 
Neuroscience 
Technologies  Microneurography Test in patients with neuropathic pain  Research Service 
Neuroscience 
Technologies  Microneurography test in animal model (rat)   Research Service 
Thrombotargets  BioplatformScreen  Research Service 
IUCT   GC-BIO-DF   Pharmaceutical Active Ingredient 
IUCT   GC-BIO-F   Pharmaceutical Active Ingredient 
IUCT   GC-BIO-TFF   Pharmaceutical Active Ingredient 
IUCT   GC-BIO-DT  Pharmaceutical Active Ingredient 
IUCT   GC-BIO-DAP  Pharmaceutical Active Ingredient 
IUCT  IUCT-S50  Biofuel 
Main financial operations in the Spanish biotechnology sector in 2007 involving Catalan biotech companies
Company Investor Concept Investment (m€)
Ab Bcn CDTI NEOTEC No Disponible NEOTEC N/A
Advancell Ceosa, Talde, A.Vila Casas,
Unisco, BCN Empren y otros
Capital Increase 7.5
Advancell CDTI Loan 2.4
Agrasys CDTI NEOTEC N/A
Era Biotech  BCN Ventures Capital Increase 0.3
Genmedica Therapeutics Uninvest-Unirisco Capital Increase 0.8
Genmedica Therapeutics BCN Ventures Capital Increase 0.8
Infinitec Activos  BCN Ventures Capital Increase 0.05
Main financial operations in the Spanish biotechnology sector in 2007 involving Catalan biotech companies
Company Investor Concept Investment (m€)
Ab Bcn CDTI NEOTEC No Disponible NEOTEC N/A
Advancell Ceosa, Talde, A.Vila Casas,
Unisco, BCN Empren y otros
Capital Increase 7.5
Advancell CDTI Loan 2.4
Agrasys CDTI NEOTEC N/A
Era Biotech  BCN Ventures Capital Increase 0.3
Genmedica Therapeutics Uninvest-Unirisco Capital Increase 0.8
Genmedica Therapeutics BCN Ventures Capital Increase 0.8
Infinitec Activos  BCN Ventures Capital Increase 0.05









Private partners Capital Increase 0.14
Omnia Molecular  CDTI  NEOTEC N/A
Thrombotargets Europe Biotech Angels Capital Increase 2
Thrombotargets Europe Biolead Capital Capital  Increase 2
Thrombotargets Europe ENISA Capital  Increase 0.6
Uni-Biofocus Caixanova









Private partners Capital Increase 0.14
Omnia Molecular  CDTI  NEOTEC N/A
Thrombotargets Europe Biotech Angels Capital Increase 2
Thrombotargets Europe Biolead Capital Capital  Increase 2
Thrombotargets Europe ENISA Capital  Increase 0.6
Uni-Biofocus Caixanova Fund participation 6